

WHAT IS CLAIMED IS:

Sub
5 1. A method of treating solid tumors in a mammal which comprises administering a therapeutically effective amount of one or more arsenic compounds to said mammal.

10 2. A method of treating metastatic neoplastic disease in a mammal which comprises administering a therapeutically effective amount of one or more arsenic compounds to a mammal in need of such therapy.

15 3. A method of treating melanoma, breast, colon, ovarian, renal, central nervous system, bladder, prostate or lung cancer in a human which comprises administering a therapeutically effective amount of one or more arsenic compounds to said human.

20 4. The method of claim 1 wherein said tumor is a tumor of epithelial tissue, lymphoid tissue, connective tissue, bone or central nervous system.

25 5. The method of claim 2 wherein said metastatic neoplastic disease is a disease of epithelial tissue, lymphoid tissue, connective tissue, bone or central nervous system.

30 6. The method of claim 4 wherein said tumor of the epithelial tissue is a tumor of epithelial glands, epithelial ducts, liver, biliary tract, gastrointestinal tract, respiratory tract, or urogenital tract.

35 7. The method of claim 4 wherein said tumor is squamous cell carcinoma of the esophagus, adenocarcinoma of the esophagus, colorectal carcinoma, or gastric carcinoma.

8. The method of claim 4 wherein said tumor of the lymphoid tissue is Hodgkins lymphoma, non-Hodgkin's

lymphoma, follicular lymphoma, diffuse lymphoma, lymphoblastic lymphoma, large cell lymphoma, or small lymphocytic lymphoma.

5 9. The method of claim 4 wherein said tumor of the central nervous system is selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma or oligodendroglioma.

10 10. The method of claim 1, 2 or 3 wherein said arsenic compound is an ionic aqueous solution of arsenic.

15 11. The method of claim 1, 2 or 3 wherein said arsenic compound is selected from the group consisting of arsenic trioxide and Fowler's solution.

20 12. The method of claim 1, 2 or 3 wherein the total daily amount administered is from about 10 μ g to about 200 mg.

25 13. A method for treating neoplastic diseases in a human which comprises administering to a human an effective amount of an arsenic compound, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of at least one other therapeutic.

30 14. The method of claim 12 in which said other therapeutic agent is a chemotherapeutic or radiotherapeutic.

35 15. The method of claim 1, 2, 3, or 12 in which said administration is made parenterally, topically, dermally, directly into the tumor or orally.

40 16. The method of claim 12 in which said other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate,

vinblastine, methotrexate, hydroxyurea, cyclophosphamide,
doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-
26(vumon), BCNU, all-trans retinoic acid, procarbazine,
cytokines, therapeutic vaccines, and other
5 immunomodulators.

17. The method of claim 1, 2, 3 or 12 in which said
administration is made via an implantation device.

18. A method of treating hematopoietic disorders in a
mammal which comprises administering one or more arsenic
compounds to said mammal, wherein said hematopoietic
disorder is selected from the group consisting of acute
15 lymphocytic leukemia, chronic lymphocytic leukemia, hairy
cell leukemia, myeloid metaplasia, myeloid dysplastic
syndrome, multiple myeloma and plasmacytoma.

19. An oral pharmaceutical composition useful for
20 treating neoplastic diseases in a human which comprises an
effective amount of an arsenic compound or a
pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier, diluent or excipient.

20. A sterile unit dosage form adapted for parenteral
25 administration which comprises a therapeutically effective
non-lethal amount of arsenic trioxide in an aqueous
carrier, said dosage form being contained in a sealed
sterile glass container.